Generalized Anxiety Disorder (GAD) Clinical Trial
— GAD_exerciseOfficial title:
Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)
NCT number | NCT02662803 |
Other study ID # | EA1/217/15 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2015 |
Est. completion date | January 2019 |
Verified date | February 2019 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study investigate the effect of high-intense aerobe exercise training (HIT) on clinical and physiological parameters (anxiety, somatisation, cortisol, alpha amylase, "mismatch negativity", loudness dependence auditory evoked potentials) in patients with generalized anxiety disorder (GAD). Half of patients will receive HIT, while the other half will receive aerobe exercise of low intensity.
Status | Completed |
Enrollment | 29 |
Est. completion date | January 2019 |
Est. primary completion date | January 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Generalized Anxiety Disorder (GAD) according to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) - Appropriate abilities to communicate and to complete the questionnaires - Written informed consent - Possibility of regular attendance at the training sessions Exclusion Criteria: - Other severe mental conditions than GAD (e.g. schizophrenia, severe depressive episode, addiction) - Acute suicidality - Epilepsy or other disorders of the central nervous system (e.g. tumor, encephalitis) - Contraindications to aerobe exercise training - Cardiovascular diseases - Start or modification of an anxiolytic pharmacotherapy within the last four weeks - Current psychotherapy |
Country | Name | City | State |
---|---|---|---|
Germany | Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Mitte | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Burgomaster KA, Hughes SC, Heigenhauser GJ, Bradwell SN, Gibala MJ. Six sessions of sprint interval training increases muscle oxidative potential and cycle endurance capacity in humans. J Appl Physiol (1985). 2005 Jun;98(6):1985-90. Epub 2005 Feb 10. — View Citation
Clark CR, McFarlane AC, Weber DL, Battersby M. Enlarged frontal P300 to stimulus change in panic disorder. Biol Psychiatry. 1996 May 15;39(10):845-56. — View Citation
Gaudlitz K, Plag J, Dimeo F, Ströhle A. Aerobic exercise training facilitates the effectiveness of cognitive behavioral therapy in panic disorder. Depress Anxiety. 2015 Mar;32(3):221-8. doi: 10.1002/da.22337. Epub 2014 Dec 17. — View Citation
Ghisolfi ES, Heldt E, Zanardo AP, Strimitzer IM Jr, Prokopiuk AS, Becker J, Cordioli AV, Manfro GG, Lara DR. P50 sensory gating in panic disorder. J Psychiatr Res. 2006 Sep;40(6):535-40. Epub 2006 Apr 17. — View Citation
Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry. 1993 Feb 1;33(3):173-87. Review. — View Citation
Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. Br J Sports Med. 2014 Feb;48(3):187-96. doi: 10.1136/bjsports-2012-091287. Epub 2013 Jan 7. Review. — View Citation
Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988 Jan-Feb;14(1):61-8. — View Citation
Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. — View Citation
Näätänen R. The mismatch negativity: a powerful tool for cognitive neuroscience. Ear Hear. 1995 Feb;16(1):6-18. Review. — View Citation
Plag J, Gaudlitz K, Schumacher S, Dimeo F, Bobbert T, Kirschbaum C, Ströhle A. Effect of combined cognitive-behavioural therapy and endurance training on cortisol and salivary alpha-amylase in panic disorder. J Psychiatr Res. 2014 Nov;58:12-9. doi: 10.1016/j.jpsychires.2014.07.008. Epub 2014 Jul 21. — View Citation
Plag J, Schumacher S, Ströhle A. [Generalized anxiety disorder]. Nervenarzt. 2014 Sep;85(9):1185-94. doi: 10.1007/s00115-014-4121-8. German. — View Citation
Schumacher S, Kirschbaum C, Fydrich T, Ströhle A. Is salivary alpha-amylase an indicator of autonomic nervous system dysregulations in mental disorders?--a review of preliminary findings and the interactions with cortisol. Psychoneuroendocrinology. 2013 Jun;38(6):729-43. doi: 10.1016/j.psyneuen.2013.02.003. Epub 2013 Mar 5. Review. — View Citation
Stöber J, Bittencourt J. Weekly assessment of worry: an adaptation of the Penn State Worry Questionnaire for monitoring changes during treatment. Behav Res Ther. 1998 Jun;36(6):645-56. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Penn State Worry Questionnaire (PSWQ, german version) | PSWQ is a questionnaire for detecting the severity of GAD | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in Screening für somatoforme Störungen (SOMS) | SOMS is a questionnaire for detecting the severity of somatisation | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in Penn State Worry Questionnaire-past week (PSWQ-PW, german version) | PSWQ-PW is a questionnaire for detecting changes in GAD-severity | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in Screening für somatoforme Störungen - 7 Tage (SOMS-7T) | SOMS-7T is a questionnaire for detecting changes in somatisation | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in Hamilton Anxiety Rating Scale (HAM-A, german version) | HAM-A is a questionnaire for detecting the severity and changes of anxiety | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in Anxiety Control Questionnaire (ACQ, german version) | ACQ is a questionnaire for evaluating the ability to control anxiety | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in saliva cortisol | Cortisol is an established marker of the psychophysiological stress response | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in saliva alpha amylase | Alpha amylase is an established marker of the psychophysiological stress response | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in mismatch negativity | Mismatch negativity is an established correlate of the central information processing | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) | |
Secondary | Change in loudness dependence auditory evoked potentials | Loudness dependence auditory evoked potentials are established correlates of the central serotonergic transmission | From baseline to post therapy (+12 days) and from baseline to follow-up (+30 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01470469 -
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
|
Phase 2 | |
Completed |
NCT02305797 -
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
|
Phase 3 | |
Active, not recruiting |
NCT05738850 -
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT06024239 -
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
|
Phase 1 | |
Withdrawn |
NCT02708472 -
Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder
|
N/A |